Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

PharmaLogic Holdings Corp., a CDMO specializing in radiopharmaceuticals, has agreed to acquire a majority stake in Agilera ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Contract Pharmaceutical Manufacturing Market is expected to reach USD 450.07 Bn by 2032, exhibiting a CAGR of 9.9% from 2025 to 2032. BURLINGAME, CA, UNITED STATES, March 12, 2025 /EINPresswire ...

SINGAPORE] Boustead Singapore’s engineering and construction business unit, under its real estate solutions division Boustead ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Major” tariffs on pharmaceutical imports are coming soon, President Donald Trump says, pledging that they’d help bring drug ...

Indian generic and formulation pharmaceutical (pharma) companies are contending with tariff-related challenges and subdued ...

Corporation has been awarded a NASA contract to launch four additional pharmaceutical drug investigations to the International ...